

→ The study lasts about **8 weeks** (50–57 days)

→ There are 4 to 6 in-person clinic visits plus phone check-ins

→ The participant will take either **IGC-AD1** or a placebo (an inactive solution that looks the same)

→ Participation can be stopped at **any time**

What to Expect



Rights and Support



Participation is **voluntary**



You may **ask questions** at **any time** before or during the study



Caregivers are recognized as partners in this process and **receive** ongoing **support** from the study team

Contact us:



calma@igcpharma.com



<https://igcpharma.com/calma>